WallStreetZenWallStreetZen

NASDAQ: ALLO
Allogene Therapeutics Inc Stock

$5.04-0.32 (-5.97%)
Updated Mar 22, 2023
ALLO Price
$5.04
Fair Value Price
$5.47
Market Cap
$728.27M
52 Week Low
$5.00
52 Week High
$17.49
P/E
-2.17x
P/B
1.09x
P/S
3,705.34x
PEG
N/A
Dividend Yield
N/A
Revenue
$243.00k
Earnings
-$332.63M
Gross Margin
100%
Operating Margin
-136,885.6%
Profit Margin
-136,885.6%
Debt to Equity
0.23
Operating Cash Flow
-$221M
Beta
1.21
Next Earnings
May 2, 2023
Ex-Dividend
N/A
Next Dividend
N/A

ALLO Overview

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Zen Score

Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ALLO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ALLO ($5.04) is undervalued by 7.9% relative to our estimate of its Fair Value price of $5.47 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ALLO ($5.04) is not significantly undervalued (7.9%) relative to our estimate of its Fair Value price of $5.47 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ALLO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ALLO due diligence checks available for Premium users.

Be the first to know about important ALLO news, forecast changes, insider trades & much more!

ALLO News

Valuation

ALLO fair value

Fair Value of ALLO stock based on Discounted Cash Flow (DCF)
Price
$5.04
Fair Value
$5.47
Undervalued by
7.90%
ALLO ($5.04) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ALLO ($5.04) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ALLO is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ALLO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-2.17x
Industry
16.9x
Market
22.44x

ALLO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.09x
Industry
4.76x
ALLO is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ALLO's financial health

Profit margin

Revenue
$47.0k
Net Income
-$94.8M
Profit Margin
-201,802.1%
ALLO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ALLO's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$817.1M
Liabilities
$151.2M
Debt to equity
0.23
ALLO's short-term assets ($528.82M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALLO's short-term assets ($528.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALLO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ALLO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$62.1M
Investing
$49.6M
Financing
$46.0k
ALLO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ALLO vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ALLO$728.27M-5.97%-2.17x1.09x
PNT$723.67M-5.91%-7.87x2.34x
MCRB$738.81M-3.78%-2.54x68.52x
PRTC$717.48M-1.85%-11.87x1.21x
PHAR$739.57M+8.99%51.12x3.40x

Allogene Therapeutics Stock FAQ

What is Allogene Therapeutics's quote symbol?

NASDAQ: ALLO) Allogene Therapeutics trades on the NASDAQ under the ticker symbol ALLO. Allogene Therapeutics stock quotes can also be displayed as NASDAQ: ALLO.

If you're new to stock investing, here's how to buy Allogene Therapeutics stock.

What is the 52 week high and low for Allogene Therapeutics (NASDAQ: ALLO)?

(NASDAQ: ALLO) Allogene Therapeutics's 52-week high was $17.49, and its 52-week low was $5.00. It is currently -71.18% from its 52-week high and 0.8% from its 52-week low.

How much is Allogene Therapeutics stock worth today?

(NASDAQ: ALLO) Allogene Therapeutics currently has 144,497,383 outstanding shares. With Allogene Therapeutics stock trading at $5.04 per share, the total value of Allogene Therapeutics stock (market capitalization) is $728.27M.

Allogene Therapeutics stock was originally listed at a price of $25.00 in Oct 11, 2018. If you had invested in Allogene Therapeutics stock at $25.00, your return over the last 4 years would have been -79.84%, for an annualized return of -32.99% (not including any dividends or dividend reinvestments).

How much is Allogene Therapeutics's stock price per share?

(NASDAQ: ALLO) Allogene Therapeutics stock price per share is $5.04 today (as of Mar 22, 2023).

What is Allogene Therapeutics's Market Cap?

(NASDAQ: ALLO) Allogene Therapeutics's market cap is $728.27M, as of Mar 24, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Allogene Therapeutics's market cap is calculated by multiplying ALLO's current stock price of $5.04 by ALLO's total outstanding shares of 144,497,383.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.